NeurAxis, Inc. (NRXS)
| Market Cap | 97.20M +220.7% |
| Revenue (ttm) | 5.32M +65.2% |
| Net Income | -8.45M |
| EPS | -0.78 |
| Shares Out | 12.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,127,094 |
| Open | 7.00 |
| Previous Close | 6.53 |
| Day's Range | 6.80 - 7.80 |
| 52-Week Range | 2.21 - 9.33 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+42.12%) |
| Est. Earnings | Nov 9, 2026 |
About NRXS
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation di... [Read more]
Financial Performance
In 2025, NeurAxis's revenue was $3.57 million, an increase of 32.89% compared to the previous year's $2.69 million. Losses were -$8.62 million, 1.92% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NRXS stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 42.12% from the latest price.
News
NeurAxis up 7% to $7.01 after announcing new insurer policy coverage
09:25 EDT NeurAxis (NRXS) up 7% to $7.01 after announcing new insurer policy coverage
Aetna deems IB-Stim by NeurAxis medically necessary
CVS Health’s (CVS) Aetna in a clinical policy bulletin announced that it considers percutaneous electrical nerve field stimulation with IB-Stim medically necessary durable medical equipment for the tr...
NeurAxis announces medical policy coverage from ‘major’ insurer
NeurAxis (NRXS) announced new medical policy coverage from a “major national health insurer” for Percutaneous Electrical Nerve Field Stimulation. The coverage spans multiple states and represents appr...
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
Total national coverage footprint for PENFS increases to over 147 million covered lives Total national coverage footprint for PENFS increases to over 147 million covered lives
NeurAxis Transcript: Lytham Partners Fall 2026 Investor Conference
The presentation highlighted strong revenue growth, expanded insurance coverage, and a strategic push into the adult market with a multi-site RCT launching in fall 2026. Leadership was strengthened with a new Chief Commercial Officer, and the company remains focused on broadening insurance access and scaling commercialization.
Neuraxis appoints Blanchard as Chief Commercial Officer
NeurAxis (NRXS) announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Blanchard will oversee the Company’s commercial functions, including sales and marketing. Previo...
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis Transcript: IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026
The conference highlighted a med tech company’s rapid growth in neuromodulation therapies for GI disorders, driven by strong clinical evidence, expanding insurance coverage, and disciplined execution. With a large addressable market and new hires to accelerate payer access, exponential revenue growth is expected over the next 15-18 months.
NeurAxis Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 116% YoY to $1.93M, with gross margin expanding to 85.9% and strong progress in insurance coverage and VA channel expansion. Cash burn improved, but future profitability depends on securing additional payer coverage and continued commercial execution.
NeurAxis Quarterly report: Q2 2026
NeurAxis has published its Q2 2026 quarterly earnings report on August 11, 2026.
NeurAxis Earnings release: Q2 2026
NeurAxis released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
NeurAxis Expands Payer Coverage with New Policies
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis Registration statement: Registration filing
NeurAxis filed a registration statement on July 30, 2026, providing details about a securities offering with the SEC.
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
Neuraxis files to sell 1.92M shares of common stock for holders
16:44 EDT Neuraxis (NRXS) files to sell 1.92M shares of common stock for holders
NeurAxis Registration statement: Registration filing
NeurAxis filed a registration statement on July 23, 2026, providing details about a securities offering with the SEC.
NeurAxis Transcript: Lytham Partners Spring 2026 Investor Conference
The company reported record Q1 revenue and strong gross margins, driven by expanded insurance coverage and a new Category 1 CPT code. Commercial efforts are focused on pediatric and VA markets, with new hires and resumed commercialization of the RED device supporting growth.
NeurAxis Slides: Investor presentation
NeurAxis has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
NeurAxis Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 80% year-over-year to $1.6 million, with gross margin expanding to 86.4% and cash burn declining. Commercial focus is on deepening adoption in covered pediatric markets and expanding VA presence, while payer coverage and execution remain key growth drivers.
NeurAxis Quarterly report: Q1 2026
NeurAxis has published its Q1 2026 quarterly earnings report on May 12, 2026.
NeurAxis Earnings release: Q1 2026
NeurAxis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...